Jump Financial LLC Acquires 20,559 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY)

Jump Financial LLC increased its holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 778.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,200 shares of the company's stock after purchasing an additional 20,559 shares during the quarter. Jump Financial LLC's holdings in Dr. Reddy's Laboratories were worth $366,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Robeco Institutional Asset Management B.V. raised its holdings in shares of Dr. Reddy's Laboratories by 453.8% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company's stock valued at $180,620,000 after acquiring an additional 9,373,412 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Dr. Reddy's Laboratories by 382.9% in the 4th quarter. Renaissance Technologies LLC now owns 9,418,428 shares of the company's stock worth $148,717,000 after purchasing an additional 7,467,979 shares in the last quarter. Aikya Investment Management Ltd lifted its position in shares of Dr. Reddy's Laboratories by 416.1% in the 4th quarter. Aikya Investment Management Ltd now owns 5,610,503 shares of the company's stock worth $88,590,000 after purchasing an additional 4,523,303 shares during the period. Vanguard Group Inc. boosted its stake in shares of Dr. Reddy's Laboratories by 397.2% during the 4th quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company's stock valued at $77,311,000 after purchasing an additional 3,911,404 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of Dr. Reddy's Laboratories by 462.1% during the fourth quarter. JPMorgan Chase & Co. now owns 2,814,710 shares of the company's stock valued at $44,444,000 after buying an additional 2,313,987 shares during the period. Hedge funds and other institutional investors own 3.85% of the company's stock.

Dr. Reddy's Laboratories Stock Down 0.6 %

RDY traded down $0.09 on Thursday, hitting $13.84. The company had a trading volume of 252,490 shares, compared to its average volume of 1,467,732. The stock has a fifty day simple moving average of $13.20 and a 200-day simple moving average of $14.19. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38. The firm has a market capitalization of $11.55 billion, a P/E ratio of 22.05 and a beta of 0.51. Dr. Reddy's Laboratories Limited has a 52-week low of $12.26 and a 52-week high of $16.89.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last released its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.01. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%. As a group, equities analysts expect that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current fiscal year.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.